Introduction {#S0001}
============

Bladder cancer is one of the most common genitourinary cancers in the world and is associated with a high morbidity and mortality rate. Because of its aggressiveness, many studies focus on the optimal treatment of bladder cancer*.*[@CIT0001]According to the European Association of Urology guidelines, radical cystectomy is recommended not only for patients with muscle-invasive bladder cancer, but also for patients with non-muscle invasive bladder cancer who are at highest risk of progression and patients with BCG (bacillus calmette--guérin)-refractory bladder cancer.[@CIT0002],[@CIT0003] However, radical cystectomy is one of the most complex urological surgical procedures, with higher complication rates.

Minimally invasive robot-assisted radical cystectomy (RARC) is the most advanced surgical approach to reduce the incidence of complications.[@CIT0004] Postoperative morbidity and mortality after RARC are lower than those in open radical cystectomy (ORC), while the oncologic outcomes are comparable.[@CIT0005]--[@CIT0008]

While the proportion of overall postoperative complications after RARC has decreased compared with complication rates of ORC (57--74%) due to advances in surgical methods and techniques, it still remains high at 35--63%. Similarly, RARC is associated with fewer major complications more than grade III or more than ORC (about 22%), but the rate of major complications is still high 10%.[@CIT0009]--[@CIT0011]

To reduce the incidence of complications following surgery, it is important to predict and prevent factors associated with the occurrence of complications. High American Society of Anesthesiologists (ASA) score, estimated blood loss (EBL), Charlson comorbidity index (CCI), and obesity are well-known predictors of perioperative complications in patients undergoing ORC.[@CIT0012],[@CIT0013] However, there is still a lack of research in postoperative complications and associated risk factors were still limited in patients underwent RARC.

Here, we evaluated postoperative complications following RARC with extracorporeal urinary diversion, and identified predictive factors for these complications following RARC with extracorporeal urinary diversion.

Material and methods {#S0002}
====================

We retrospectively reviewed 126 consecutive patients who underwent RARC with extracorporeal urinary diversion from August 2008 to November 2017. Age at the time of surgery, sex, body mass index (BMI), ASA score, preoperative hemoglobin, history of previous abdominal surgery, history of intravesical instillation, history of neoadjuvant chemotherapy, pathologic stage, operative time, EBL, and type of urinary diversion were included as demographic data and perioperative data. This study was approved by the International Review Board of Samsung Medical Center (approval number: 2018--05-146) with the Declaration of Helsinki. For this type of study, formal consent was not required and data were anonymous.

Complications were classified according to the modified Clavien-Dindo system.[@CIT0014] Major complications were defined as Clavien-Dindo grade Ⅲ or greater, while minor complications were defined as Clavien-Dindo grade Ⅱ or less. Multiple complications were defined as the presence of more than one complication in the same patient.

The following descriptive statistics were used for continuous data: mean, standard deviation, and 95% confidence interval (CI) or median and interquartile range (IQR). Predictive factors for complications after RARC were determined using a multivariate logistic regression model and calculating the odds ratio (OR) and 95% CI. Multivariate analyses were performed with only significant factors as judged by univariate analysis.

Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and R 3.4.3 (Vienna, Austria; <http://www.R-project.org/>). Values of *p*\<0.05 were considered statistically significant.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

Baseline demographics of patients are presented in [Table 1](#T0004){ref-type="table"}. The mean age of patients with RARC was 61.7±10.7. RARC was performed primarily in males (91.3%, n=115). Mean preoperative hemoglobin was 13.4±1.8, and patients who had previously undergone abdominal surgery comprised 15.9% (n=20). Among patients with RARC, 20.6% (n=26) underwent intravesical instillation (except for three patients who received epirubicin intravesical instillation), and all patients underwent BCG intravesical instillation, while 15.1% (n=19) of patients underwent neoadjuvant chemotherapy. T3 pathology was the most common (37.3%, n=47), and LN (lymph node) metastasis was confirmed in 27.8% (n=35) of patients ([Table 1](#T0004){ref-type="table"}). Table 1Patient demographicsVariableValueAge, year61.7±10.7Sex, n (%) Male115 (91.3) Female11 (8.7)BMI, n (%) \<18.55 (4.0) 18.5--22.950 (39.7) 23.0--24.926 (20.6) ≥25.045 (35.7)Preoperative hemoglobin13.4±1.8CCI, n (%) 3 or lower44 (34.9) 441 (32.5) 524 (19.0) 6 or higher17 (13.5)ASA score, n (%) 137 (29.4) 284 (66.7) 35 (4.0)Previous abdominal surgery, n (%) Yes20 (15.9) No106 (84.1)Intravesical instillation, n (%) Yes\*26 (20.6) No100 (79.4)Neoadjuvant chemotherapy, n (%) Yes19 (15.1) No107 (84.9)Pathologic stage, n (%) T07 (5.6) Ta1 (0.8) Tcis10 (7.9) T123 (18.3) T226 (20.6) T347 (37.3) T412 (9.5)LN metastasis, n (%)35 (27.8)[^2]

Perioperative data {#S0003-S2002}
------------------

Perioperative data are shown in [Table 2](#T0005){ref-type="table"}. Median overall operation time was 500 minutes (IQR, 435--585), median EBL was 400 mL (IQR, 300--600), median hospital stay was 23 days (IQR, 17--32), and median follow-up was 22.4 months (IQR, 8.0--43.0). The diversion type of RARC was preferred to ileal conduit (68.3%, n=86) compared to neobladder formation (31.7%, n=40). In patients with ileal neobladder, longer operative times (527 minutes \[IQR, 465--655\] vs 445 minutes \[IQR, 372--526\]) and longer hospital stays (25 days \[IQR, 20--33\] vs 17 days \[IQR, 16--21\]) were recorded than patients with ileal conduit. However, EBL did not significantly differ between ileal neobladder and ileal conduit (450 minutes \[IQR, 300--600\] vs 400 minutes \[IQR, 300--600\]). Transfusions were performed in 34 patients (27%), most of which were performed postoperatively (30 patients, 23.8%), with intraoperative transfusions performed in 8 patients (6.3%) ([Table 2](#T0005){ref-type="table"}). Table 2Perioperative dataVariableValueMedian overall operation time, min500 (435--585) Ileal conduit445 (372--526) Neobladder (studer)527 (465--655)Median EBL, mL400 (300--600) Ileal conduit400 (300--500) Neobladder (studer)450 (300--600)LN removal, n (%) Yes120 (95.2) Mean LN removal20.1±8.9 No6 (4.8)Type of urinary diversion, n (%) Ileal conduit40 (31.7) Neobladder (studer)86 (68.3)Transfusion, n (%)34 (27.0) Intraoperative8 (6.3) Postoperative30 (23.8)Surgical margin positive, n (%) Yes9 (7.1) Ureter6 (4.8) Perivesical tissue2 (1.6) Vas deferens1 (0.8) No117 (92.9)Median hospital stays, day23 (17--32) Ileal conduit17 (16--21) Neobladder (studer)25 (20--33)Time to flatus, day3.6±3.2Median follow up, month22.4 (8.0--43.0) Ileal conduit18.3 (7.8--42.3) Neobladder (studer)26.1 (9.1--43.0)[^3]

Complications {#S0003-S2003}
-------------

Complications occurred in 78 patients (61.9%). Total 95 minor complications occurred in 73 patients (57.9%), 5 major complications occurred in 5 patients (4.0%), and multiple complications occurred in 22 patients (17.5%).

Grade Ⅰ complication occurred in 27 patients (21.4%), grade Ⅱ complication occurred in 68 patients (54.0%), grade Ⅲa complication occurred in 2 patients (1.6%), and grade Ⅲb complication occurred in 3 patients (2.4%). Complication of grade Ⅳ or higher did not occur ([Table 3](#T0006){ref-type="table"}). Table 3Clavien-Dindo classifications of complications following RARCNo. (%)Patients with complications, n (%)78 (61.9) Patients with minor complications, n (%)73 (57.9) Patients with major complications, n (%)5 (4.0) Patients with multiple complications, n (%)22 (17.5)Total number of complications100 Grade Ⅰ complications, n (%)27 (27.0) Grade Ⅱ complications, n (%)68 (68.0) Grade Ⅲ a or greater complications, n (%)5 (5.0)Highest complications grade, n (%) No complications48 (38.1) Grade Ⅰ20 (15.9) Grade Ⅱ53 (42.1) Grade Ⅲa2 (1.6) Grade Ⅲb3 (2.4) Grade Ⅳ0 (0) Grade Ⅴ0 (0)[^4]

Detailed complications following RARC are listed in [Table 4](#T0007){ref-type="table"}. The most frequent complications were transfusion (27.0%, n=34), febrile urinary tract infection (15.9%, n=20), anastomosis site leakage (14.3%, n=18), and ileus (10.3%, n=13). A classification of complications and specific complications according to diversion type and pathologic results are listed in [Tables S1](#T0004){ref-type="table"} and [2](#T0005){ref-type="table"}. In addition, a classification of complications and specific complications according to intravesical instillation are also listed in [Table S3](#T0006){ref-type="table"}. Table 4Detailed complications following RARCComplicationsNo. (%)Transfusion34 (27.0)UTI (febrile)20 (15.9)Anastomosis site leakage18 (14.3)Ileus13 (10.3)Wound problem5 (4.0) Grade Ⅰ2 (1.6) Grade Ⅲa2 (1.6) Grade Ⅲb1 (0.8)Lymphocele2 (1.6)Bowel injury2 (1.6)Operation site fluid collection2 (1.6) Grade Ⅰ1 (0.8) Grade Ⅲa1 (0.8)Scrotal edema2 (1.6)Anastomosis site stricture1 (0.8)Pulmonary thromboembolism1 (0.8)[^5]

Predictors of complications {#S0003-S2004}
---------------------------

In univariate analysis, intravesical instillation (OR=3.168, 95% CI=1.10--9.07, *p*=0.0318) and EBL (OR=3.159, 95% CI=1.452--6.876, *p*=0.0037) were significant predictors associated with complications following RARC. In multivariate analysis, intravesical instillation (OR=3.374, 95% CI =1.116--10.197, *p*=0.0312), EBL (OR=3.949, 95% CI=1.682--9.27, *p*=0.0016), and preoperative hemoglobin (OR=0.751, 95% CI=0.588--0.96, *p*=0.022) were significant predictors associated with complications following RARC ([Table 5](#T0008){ref-type="table"}.). Table 5Logistic regression model to identify predictive factors for postoperative complications following RARCUnivariable analysisMultivariable analysisOR (95% CI)*p*OR (95% CI)*p*Age0.996 (0.963--1.031)0.8333Sex MaleReference Female1.714 (0.432--6.803)0.4438BMI \<25Reference ≥250.763 (0.362--1.609)0.4775Preoperative hemoglobin0.816 (0.661--1.008)0.05940.751 (0.588--0.96)0.022ASA score0.7174 1Reference 20.807 (0.322--2.018)1 31.652 (0.144--18.944)1Abdominal surgery history NoReference Yes1.531 (0.545--4.3)0.4187Urinary diversion type ConduitReference Neobladder1.778 (0.828--3.821)0.1402Intravesical instillation NoReferenceReference Yes3.168 (1.106--9.078)0.03183.374 (1.116--10.197)0.0312Neoadjuvant chemotherapy NoReference Yes0.821 (0.305--2.212)0.6964EBL3.159 (1.452--6.876)0.00373.949 (1.682--9.27)0.0016LN removal0.971 (0.935--1.009)0.1305Operation time1.001 (0.999--1.004)0.3373Operation year0.92 (0.812--1.042)0.1913[^6]

Discussion {#S0004}
==========

In this study, we investigated complications following RARC and factors affecting the occurrence of complications after RARC. We found that preoperative hemoglobin, EBL, and intravesical instillation were significant predictors of complications following RARC.

Previous studies have shown that overall complication rates after RARC vary from center to center. According to Al-Daghmin et al in RARC with mainly extracorporeal conduit diversion, the overall complication rate is 77%, the low-grade complication rate is 58%, and the high-grade complication rate is 19%.[@CIT0015] According to Yuh et al in RARC with mainly extracorporeal continent diversion, the overall complication rate is 82%, the low-grade complication rate is 45%, and the high-grade complication rate is 37%.[@CIT0016] According to Nazmy et al in RARC with mainly extracorporeal continent diversion, the overall complication rate is 77%, the low-grade complication rate is 45%, and the high-grade complication rate is 32%.[@CIT0017] In contrast, we found that the incidence of overall complications after RARC was lower (61.9%) in our study. While rates of low-grade (Clavien-Dindo grade 1 or 2) complications after RARC (57.9%) were similar, rates of high-grade complications (Clavien-Dindo grade 3 or 4) were much lower than those in previous reports (4%).

Many previous studies have explored predictors of complications following RARC. According to Nazmy et al, ASA, preoperative hematocrit, and diversion type contribute to any grade of complications after RARC.[@CIT0017] Yuh et al identified age, ASA, preoperative hematocrit, operation time, EBL, and diversion type as predictors of complications after RARC.[@CIT0018] However, according to Abe et al there were no significant differences in overall complications according to diversion type,[@CIT0019] while according to Tan et al preoperative anemia is not associated with increased preoperative complications in patients treated with RARC.[@CIT0020] Notably, we identified intravesical instillation (OR=3.374) as a novel unfavorable predictive factor for complications after RARC, in addition to preoperative hemoglobin (OR=0.751) and EBL (OR=3.949). Because intravesical instillation was a significant factor for complications following RARC, more careful procedures are needed when operating on patients with intravesical instillation history. Additionally, preoperative hemoglobin control through anemia correction or nutritional support and careful bleeding control during surgery are necessary to reduce complications after RARC.

We hypothesized that there are unknown effects of intravesical instillation resulting in complications, including anatomical modifications such as mucosal changes in the bladder and deterioration of immunity after performing transurethral resection of the bladder several times before intravesical instillation or intravesical instillation. In fact, bladder contracture or necrosis has been reported with local side effects after BCG intravesical instillation,[@CIT0021] and a previous study found that BCG intravesical instillation causes modulation of peripheral immune mechanisms in addition to local immune activation.[@CIT0022]

There are some limitations of this study. First, the study was retrospective and analyzed a relatively small quantity of data. Second, we conducted the study in a single tertiary center and cannot rule out selection bias. Third, we included only RARC with extracorporeal urinary diversion, so it is difficult to generalize our results to RARC as a whole. Fourth, our analysis did not reflect the improvement of the surgeon's RARC technique over time. More accurate results would be obtained by analyzing the learning curve of the surgeon. Finally, our results may reflect minor complications rather than major complications, because few major complications occurred. Additionally, in this study we do not adjust enhanced recovery after surgery (ERAS) protocol to all patients because the ERAS protocol introduced in urologic surgery relatively recently.

Briefly mention about ERAS protocol, it is a multimodal perioperative care pathway designed to achieve early recovery for patients undergoing major surgery.[@CIT0023] ERAS protocol was applied first at colorectal surgery to decrease complications after surgery and introduced in urologic surgery especially in radical cystectomy relatively recently.[@CIT0024] There is a meta-analysis of the effect of ERAS protocol on perioperative outcomes after radical cystectomy that shows reduction in length of the index hospitalization, decrease in the rate of low-grade complications, and improvement of the time-to-bowel function, so the benefit of applying the ERAS protocol to radical cystectomy is expected to be substantial.[@CIT0025] We expect the further reduction of complications by applying ERAS protocol to RARC, especially in ileus.

Nevertheless, our study has strength in relatively large amount of RARC cases from single institution. And it is significant that our study reemphasizes exisiting predictors of complications following RARC and presents new predictors, such as history of intravesical instillation.

Conclusion {#S0005}
==========

We detected that the rates of major complications were comparable after RARC with extracorporeal urinary diversion compared as reported in previous studies and lower major than minor complications following RARC in our study. The predictors of postoperative complications following RARC were intravesical instillation, preoperative hemoglobin, and EBL during surgery. Our results offer valuable information that may help clinicians to reduce complications following RARC.
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Table S1Clavien-Dindo classifications of postoperative complications and specific complications following RARC according to type of urinary diversionIleal conduit (N=40)Ileal neobladder (N=86)Patients with complications, n (%)21 (52.5)57 (66.3) Patients with minor complications, n (%)19 (47.5)54 (62.8) Patients with major complications, n (%)2 (5.0)3 (3.0) Patients with multiple complications, n (%)7 (17.5)15 (17.4)Total number of complications2971 Minor complications, n (%)27 (93.1)68 (95.8) Major complications, n (%)2 (6.9)3 (4.2)Highest complications grade, n (%) No complications19 (47.5)29 (33.7) Grade Ⅰ4 (10.0)16 (1.6 Grade Ⅱ15 (37.5)38 (44.2) Grade Ⅲa1 (2.5)1 (1.2) Grade Ⅲb1 (2.5)2 (2.3)Specific complications, n (%) Transfusion15 (37.5)19 (22.1) UTI (febrile)1 (2.5)19 (22.1) Anastomosis site leakage1 (2.5)17 (19.8) Ileus4 (10.0)9 (10.5)[^7] Table S2Clavien-Dindo classifications of postoperative complications and specific complications following RARC according to pathologic resultsT0, Tcis, Ta, T1, T2 (N=67)T3, T4 (N=59)Patients with complications, n (%)44 (65.7)34 (57.6) Patients with minor complications, n (%)39 (58.2)34 (57.6) Patients with major complications, n (%)5 (7.5)0 (0.0) Patients with multiple complications, n (%)14 (20.9)8 (13.6)Total number of complications5842 Minor complications, n (%)53 (91.4)42 (100.0) Major complications, n (%)5 (8.6)0 (0.)Highest complications grade, n (%) No complications23 (34.3)25 (42.4) Grade Ⅰ9 (13.4)11 (18.6) Grade Ⅱ30 (44.8)23 (39.0) Grade Ⅲa2 (3.0)0 (0.0) Grade Ⅲb3 (4.5)0 (0.0)Specific complications, n (%) Transfusion18 (26.9)16 (27.1) UTI (febrile)12 (17.9)8 (13.6) Anastomosis site leakage10 (14.9)8 (13.6) Ileus8 (11.9)5 (8.5)[^8] Table S3Clavien-Dindo classifications of postoperative complications and specific complications following RARC according to intravesical instillationIntravesical instillation (N=26)No intravesical instillation (N=100)Patients with complications, n (%)21 (80.8)57 (57.0) Patients with minor complications, n (%)27 (103.8)68 (54.0) Patients with major complications, n (%)1 (3.8)4 (4.0) Patients with multiple complications, n (%)6 (23.1)16 (16.0)Total number of complications2872 Minor complications27 (96.4)68 (94.4) Major complications1 (3.6)4 (5.6)Highest complications grade, n (%) No complications5 (19.2)43 (43.0) Grade Ⅰ4 (15.4)16 (16.0) Grade Ⅱ16 (61.5)37 (37.0) Grade Ⅲa1 (3.8)1 (1.0) Grade Ⅲb0 (0)3 (3.0)Specific complications, n (%) Transfusion10 (38.5)24 (24.0) UTI (febrile)7 (26.9)13 (13.0 Anastomosis site leakage3 (11.5)15 (15.0) Ileus3 (11.5)10 (10.0)[^9]

[^1]: These authors contributed equally to this work

[^2]: **Notes:** \*Except for 3 (epirubicin intravesical instillation), all patients underwent BCG intravesical instillation.

    **Abbreviations:** BMI, body mass index; CCI, Charlson comorbidity index; ASA, American Society of Anesthesiologists; LN, lymph node; BCG, bacillus calmette--guérin.

[^3]: **Abbreviations:** EBL, estimated blood loss; LN, lymph node.

[^4]: **Abbreviations:** RARC, robot-assisted radical cystectomy; EBL, estimated blood loss; LN, lymph node.

[^5]: **Abbreviations:** RARC, robot-assisted radical cystectomy; UTI, urinary tract infection.

[^6]: **Abbreviations:** RARC, robot-assisted radical cystectomy; OR, odds ratio; CI, confidence interval; BMI, body mass index; ASA, American Society of Anesthesiologists; EBL, estimated blood loss; LN, lymph node.

[^7]: **Abbreviations:** RARC, robot-assisted radical cystectomy; UTI, urinary tract infection.

[^8]: **Abbreviations:** RARC, robot-assisted radical cystectomy; UTI, urinary tract infection.

[^9]: **Abbreviations:** RARC, robot-assisted radical cystectomy; UTI, urinary tract infection.
